Mankind Pharma announced a 20.8% increase in revenue for Q2 FY26, driven by strong performance in chronic and BSV consolidation. Revenue reached INR 3,697 Crore, with an EBITDA margin of 25.0%. The company remains confident in its long-term growth strategy, focusing on its base business, specialty chronic segments, OTC potential, and the BSV portfolio.
Q2 FY26 Financial Highlights
Mankind Pharma reported a revenue increase of 20.8% for Q2 FY26, reaching INR 3,697 Crore. Domestic revenue grew by 14.5% to INR 3,184 Crore, while exports surged by 82.6% YoY to INR 513 Crore. EBITDA margin stood at 25.0%, and the PAT margin was 14.1%.
Diluted EPS was reported at INR 12.4.
H1 FY26 Performance Overview
For the first half of FY26, Mankind Pharma’s revenue from operations reached INR 7,268 Crore, reflecting a 22.6% YoY growth. Domestic revenue grew by 16.6% to INR 6,285 Crore, and exports increased by 81.9% to INR 982 Crore. The EBITDA margin for H1 FY26 was 24.4%, with a PAT margin of 13.3%.
Diluted EPS for H1 FY26 was INR 23.0.
Domestic Business Performance
The domestic business registered a growth of 15% YoY, driven by the base business and BSV consolidation. The company continued to outperform in chronic segments, with growth exceeding 1.3x in Cardiac and 1.2x in Anti-Diabetics and Respiratory.
Consumer Healthcare
Revenue in the consumer healthcare segment declined by 3% YoY in Q2 FY26, due to supply chain disruptions. However, MT & E-Com share increased to 12% in H1 FY26, supported by growth exceeding 45%.
Growth Outlook
Mankind Pharma is confident in delivering sustainable long-term growth, focusing on its base business, specialty chronic segments, OTC business potential, and the super-specialty BSV portfolio.
Source: BSE
